Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission -43% Improvement Relative Risk Küçükakkaş et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 17 patients in Turkey Study underpowered to detect differences Küçükakkaş et al., Research Square, doi:10.21203/ Favors HCQ Favors control
The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients
Küçükakkaş et al., Research Square, doi:10.21203/ (Preprint)
Küçükakkaş et al., The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients, Research Square, doi:10.21203/ (Preprint)
Jul 2021   Source   PDF  
  All Studies   Meta
Retrospective 17 rheumatoid arthritis COVID-19+ patients, 7 on HCQ treatment, showing no significant differences. They study reports only including hospitalized patients, but the results include non-hospitalized patients. Results do not reflect potential difference in the probability that a case is serious enough to have been tested and identified. Few group details are provided (even the age of patients in each group is not specified). This study is excluded in the after exclusion results of meta analysis: minimal details of groups provided.
risk of ICU admission, 42.9% higher, RR 1.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 10 (10.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Küçükakkaş et al., 20 Jul 2021, retrospective, Turkey, preprint, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: The effect of hydroxychloroquine against SARSCoV-2 infection in rheumatoid arthritis patients Okan Küçükakkaş (  ) Bezmialem Vakıf University Teoman Aydın Bezmialem Vakıf University Research Article Keywords: SARS-CoV-2, hydroxychloroquine, rheumatoid arthritis, prophylaxis, treatment DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract INTRODUCTION: The effectiveness of hydroxychloroquine in SARS-CoV-2 prophylaxis and treatment is still controversial. In this study, our aim is to investigate the potential effects of hydroxychloroquine therapy on patients with diagnosed with rheumatoid arthritis and a con rmed SARS-CoV-2 infection. METHOD: We included patients who were followed up with a diagnosis of rheumatoid arthritis and whose SARS-CoV-2 infection was con rmed. The patients were divided into two groups as those who previously used hydroxychloroquine and those who did not, and were compared in terms of clinical and laboratory data. RESULTS: Our study included 17 patients with adequate data (2 males, 15 females). The mean age of the patients was 57.2 ± 11.6 years. 7 (41.2%) patients were receiving hydroxychloroquine regularly for the last 6 months. When the effect of hydroxychloroquine on clinical and laboratory parameters of patients was examined, there was no signi cant difference between the groups of patients using and not using hydroxychloroquine. The patients using and not using hydroxychloroquine were compared for the presence of typical SARS-CoV-2 infection ndings on computed tomography images, admission to the hospital and intensive care. No signi cant differences were observed between these two groups. CONCLUSIONS: Many studies on the effectiveness of hydroxychloroquine use in SARS-CoV-2 infection are still ongoing. Due to its importance in rheumatology practice, it is very important to clarify the position of hydroxychloroquine in SARS-CoV-2 therapy. Our ndings suggest that having previously used hydroxychloroquine does not have any negative or positive effect on the infection.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop